Germantown, MD, United States of America

Steven R Fuhrmann

This inventor holds 7 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Valneva Austria Gmbh, Valneva USA, Inc., Benevir Biopharm, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven R Fuhrmann. Retrieved from https://idiyas.com/inventor/steven-r-fuhrmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

Benevir Biopharm, Inc.

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12324831 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2025-06-10),

2. 11478540 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-10-25),

3. 11357844 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-06-14),

4. 10821166 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2020-11-03),

5. 10357557 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2019-07-23),

6. 10232003 - Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof (2019-03-19),

7. 9598472 - [object Object] (2017-03-21),

Title: The Innovations of Steven R Fuhrmann

Introduction

Steven R Fuhrmann is a notable inventor based in Germantown, MD (US). He holds a total of 7 patents, showcasing his contributions to the field of biotechnology. His work primarily focuses on the development of isolated polypeptides that have significant applications in neutralizing toxins.

Latest Patents

Among his latest patents is the invention titled "Isolated polypeptide of the toxin A and toxin B proteins and uses thereof." This invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides that comprise the receptor binding domains of toxin A and toxin B, as detailed in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. These isolated polypeptides are designed to neutralize the toxic effects of toxin A and/or toxin B, highlighting their potential therapeutic applications.

Career Highlights

Throughout his career, Steven has worked with prominent companies in the biotechnology sector, including Valneva Austria GmbH and Valneva USA, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field.

Collaborations

Steven has collaborated with notable professionals in his field, including Larry R Ellingsworth and David Flyer. These collaborations have likely enriched his work and expanded the impact of his inventions.

Conclusion

Steven R Fuhrmann's contributions to biotechnology through his patents and collaborations demonstrate his commitment to innovation. His work in developing isolated polypeptides for toxin neutralization is a testament to his expertise and dedication to advancing scientific knowledge.

Profile summary based on public USPTO records.